Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro
Open accessThe DOI matches its Crossref record.
Abstract
Cryptococcus neoformans infections in patients with AIDS are often incurable, despite aggressive antifungal therapy. Combination regimens with additive or synergistic drugs could provide additional options for treating cryptococcal meningitis. We evaluated the efficacy of combination therapies using L-743,872, a pneumocandin antifungal drug, and amphotericin B or fluconazole against 18 strains of C. neoformans, including 11 C. neoformans var. neoformans, 3 C. neoformans var. gattii, and 4 fluconazole-resistant isolates. The combination of subinhibitory concentrations of L-743,872 with amphotericin B significantly enhanced amphotericin B activity against C. neoformans as measured by turbidity (antifungal susceptibility studies using the National Committee of Clinical and Laboratory Standards method), quantitative CFU, and tetrazolium salt reduction assays. Similarly, the addition of subinhibitory concentrations of L-743,872 to fluconazole enhanced fluconazole activity, but the effect was less dramatic than for the pneumocandin-amphotericin B combination. A marked synergism was observed in all combinations of amphotericin B and L-743, 872 (fractional inhibitory concentration index [FIC] of < or = 0.5). Fluconazole-resistant strains showed a susceptibility to amphotericin B and L-743,872 which was comparable to that of susceptible isolates. Combinations of pneumocandin with fluconazole revealed different activities for the various strains, including synergism (FIC < 1.0), additivity (FIC = 1.0), and autonomy (FIC between 1.0 and 2.0). Combination studies with fluconazole and L-743,872 showed additive and autonomous activities against fluconazole-resistant isolates. No antagonistic interactions (FIC < 2.0) were observed for any combination of L-743,872 with either amphotericin B or fluconazole. The results of this study suggest that L-743,872 can enhance the efficacy of fluconazole or amphotericin B in vitro and indicate a potential role for L-743,872 in combination therapy against C. neoformans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Cell Wall Assembly in Saccharomyces cerevisiae
Lesage, G., & Bussey, H. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00038-05 · Cited by 849
The contribution of melanin to microbial pathogenesis: Melanin and microbial pathogenesis
Nosanchuk, J. D., & Casadevall, A. (2003) · Cellular Microbiology · doi:10.1046/j.1462-5814.2003.00268.x · Cited by 650
Self-citationRegulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541
“Other azoles have also been reported to exert antagonistic effects on amphotericin B activity (31, 185, 216, 217), and preexposure with more-lipophilic TABLE 4—Continued Combination Settings studied General findings Comments Caspofungin or anidulafungin FLC In vitro (169)b Indifference FLC reduced caspofungin activity…”
BackgroundInfluentialAntifungal Resistance and New Strategies to Control Fungal Infections
Vandeputte, P., Ferrari, S., & Coste, A. T. (2012) · International Journal of Microbiology · doi:10.1155/2012/713687 · Cited by 505
Pei, R., Zhou, F., Ji, B., & Xu, J. (2009) · Journal of Food Science · doi:10.1111/j.1750-3841.2009.01287.x · Cited by 413
Impact of Melanin on Microbial Virulence and Clinical Resistance to Antimicrobial Compounds
Nosanchuk, J. D., & Casadevall, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00545-06 · Cited by 408
Self-citationGroll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Antifungal Peptides: Novel Therapeutic Compounds against Emerging Pathogens
De Lucca, A. J., & Walsh, T. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.1.1 · Cited by 337
Combination Treatment of Invasive Fungal Infections
Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., & Ghannoum, M. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.163-194.2005 · Cited by 308
Saravolatz, L. D., Deresinski, S. C., & Stevens, D. A. (2003) · Clinical Infectious Diseases · doi:10.1086/375080 · Cited by 293
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285
In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium spp
Arikan, S., Lozano-Chiu, M., Paetznick, V., & Rex, J. H. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.245-247.2002 · Cited by 280
Del Poeta, M., Cruz, M. C., Cardenas, M. E., Perfect, J. R., & Heitman, J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.739-746.2000 · Cited by 169
Cruz, M. C., Goldstein, A. L., Blankenship, J., Del Poeta, M., Perfect, J. R., McCusker, J. H., Bennani, Y. L., Cardenas, M. E., & Heitman, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3162-3170.2001 · Cited by 159
Caspofungin: first approved agent in a new class of antifungals
Johnson, M. D., & Perfect, J. R. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.5.807 · Cited by 85
“However, when combined with other agents in vitro such as fluconazole, amphotericin B or the calcineurin inhibitor – tacrolimus, caspofungin may augment activity of these agents [39,40].”
BackgroundSurvival in the Presence of Antifungals
Meyer, V., Damveld, R. A., Arentshorst, M., Stahl, U., van den Hondel, C. A. M. J. J., & Ram, A. F. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705856200 · Cited by 85
Pianalto, K. M., Billmyre, R. B., Telzrow, C. L., & Alspaugh, J. A. (2019) · Genetics · doi:10.1534/genetics.119.302290 · Cited by 41
“In this assay, we did not observe synergy between caspofungin and Nikkomycin Z, one of the few known inhibitors of chitin synthesis in some fungi (Gaughran et al. 1994; Li and Rinaldi 1999).”
MethodWinski, C. J., Qian, Y., Mobashery, S., & Santiago-Tirado, F. H. (2022) · mBio · doi:10.1128/mbio.01539-22 · Cited by 37
“Checkerboard assays to assess the fractional inhibitory concentrations (FICs) for combinations of 409 antifungal drugs was performed as previously described (50).”
Method
Metadata
- Authors
- Franzot, S. P., & Casadevall, A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1997-02
- Volume
- 41
- Issue
- 2
- Pages
- 331-336
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1483928064
- Cited by
- 124
- References
- 0
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.